NEUROCRINE BIOSCIENCES INC Form SC 13G/A February 17, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 3)

Under the Securities Exchange Act of 1934

Neurocrine Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

64125C109

(CUSIP Number)

December 31, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b) o Rule 13d-1(c) oRule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form SC 13G/A

CUSIP No. 64125C109 13G/A Page 2 of 7 Pages

names of reporting persons

i.r.s. identification no. of above persons (entities only)

1.

Perceptive Advisors LLC

2.	check the appropriate box if a	(a) o
2.	group*	(b) o
	sec use only	

3.

citizenship or place of organization

4. **Delaware, United States of America**

number o shares	5. sole voting power	0
beneficia owned by	- o snared voling power	3,565,267
each reporting	7. sole dispositive power	0
person with:	8. shared dispositive power	3,565,267
9.	aggregate amount beneficially owned by each reporting person	y 3,565,267
10.	check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	0
11.	percent of class represented b amount in row (9)	^y 4.69%
12.	type of reporting person (See Instructions)	IA

CUSIP No. 64125C109 13G/A Page 3 of 7 Pages

names of reporting persons

i.r.s. identification no. of above persons (entities only)

13.

Joseph Edelman

14.	check the appropriate box if a	(a) o
17.	group*	(b) o
	sec use only	

15.

citizenship or place of organization

16. United States of America

number of shares	f 17. sole voting power	0
beneficia owned by	* 18 shared voting power	3,565,267
each reporting	19. sole dispositive power	0
person with:	20. shared dispositive power	3,565,267
21.	aggregate amount beneficially owned by each reporting perso	3,565,267
22.	check box if the aggregate amount in row (9) excludes certain shares (See Instructions	0 5)
23.	percent of class represented by amount in row (9)	4.69%
24.	type of reporting person (See Instructions)	IN

CUSIP No. 64125C109 13G/A Page 4 of 7 Pages

Item 1.

(a) Name of Issuer: Neurocrine Biosciences, Inc.

Address of	12780 El Camino Real	
Issuer's Principal	San Diego, CA 92130	
^(b) Executive Offices:	San Diego, CA 92130	

Item 2.

	This Schedule 13G/A (the
	"Schedule") is being filed with
	respect to shares of Common
	Stock (as defined below) of
Name of Person	Neurocrine Biosciences, Inc.
(a) Name of Person Filing:	(the "Issuer") which are
Timig.	beneficially owned by
	Perceptive Advisors LLC and
	Joseph Edelman (together, the
	"Reporting Persons"). See Item
	4 below.
Address of Principal Busine (b) Office or if pope	ss 499 Park Avenue, 25th Floor
(^{b)} Office or, if none Residence:	e ⁷ New York, NY 10022
	Perceptive Advisors LLC is a
(c) Citizenship:	Delaware limited liability company and Joseph Edelman
	is a United States Citizen.
(d) Title of Class of Securities:	Common Stock

(e) CUSIP Number: 64125C109

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) oBroker or dealer registered under section 15 of the Act (15 U.S.C. 780).

(b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)oInvestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

(e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(i)(F);

(g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) oGroup, in accordance with §240.13d-1(b)(1)(ii)(J).

CUSIP No. 64125C109 13G/A Page 5 of 7 Pages

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

The Reporting Persons beneficially own 3,565,267 shares of Common Stock which are held by an investment fund (the "Fund") to Amount which (a) beneficially Perceptive owned: Advisors LLC serves as the investment manager. Mr. Edelman is the managing member of Perceptive Advisors LLC. The beneficial ownership percentages are based on the 76,005,155 outstanding shares of (b) Percent of class: Common Stock of the Issuer, as disclosed on the Issuer's Form 10-Q filed with the SEC on November 14, 2014, Number of shares (c) as to which the person has: 0 (i)

(ii)	Sole power to vote or to direct the vote: Shared power to vote or to 3,565,267 direct the vote:
(iii)	Sole power to dispose or to direct the disposition of:
(iv)	Shared power to dispose or to direct 3,565,267 the disposition of:

Item 5 Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x.

Item 6 Ownership of More Than Five Percent on Behalf of Another Person

The Fund described in Item 4 has the right to receive or the power to direct the receipt of dividends from, or the proceeds from, the sale of the securities held in its account. Filing of this statement by the Reporting Persons shall not be deemed an admission that they beneficially own the securities reported herein. The Reporting Persons expressly disclaim beneficial ownership of all securities reported herein.

CUSIP No. 64125C109 13G/A Page 6 of 7 Pages

Item Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by theParent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification

The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were a) acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of

(a) or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. x

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form SC 13G/A

CUSIP No. 64125C109 13G/A Page 7 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 17, 2015 Date

PERCEPTIVE ADVISORS LLC

<u>/s/ Joseph Edelman</u> Signature

Joseph Edelman/Managing Member Name/Title

February 17, 2015 Date

<u>/s/ Joseph Edelman</u> Signature

Joseph Edelman Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* §240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)